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Neuroﬁ bromatosis type 1: a multidisciplinary approach to care
Angela C Hirbe, David H Gutmann
Neuroﬁ bromatosis type 1 is a relatively common inherited disorder. Patients have a high predisposition to develop 
both benign and malignant tumours. Although many manifestations of neuroﬁ bromatosis type 1 aﬀ ect the 
nervous system, other organs and tissues can also be aﬀ ected. Because of the varying features and clinical 
heterogeneity inherent to this disorder, patients can present to diﬀ erent medical and surgical specialists and, 
therefore, the association of clinical symptoms with neuroﬁ bromatosis type 1 might not be appreciated. Thus, for 
prompt diagnosis and to provide optimum care for patients with neuroﬁ bromatosis type 1, clinicians must be 
aware of the diverse clinical features of this disorder. We advocate a multidisciplinary approach to care, entailing 
a dedicated team of specialists throughout the lifetime of the patient. As our understanding of this disorder 
deepens through basic laboratory and clinical investigations, swift implementation of new eﬀ ective treatments 
becomes feasible.
Introduction
Neuroﬁ bromatosis type 1 is a relatively common inherited 
disorder that aﬀ ects about one in 2500 to one in 3000 
people world wide, irrespective of sex or ethnic origin.1,2 
Individuals with neuroﬁ bromatosis type 1 are prone to 
develop benign and malignant tumours of the CNS and 
peripheral nervous system, in addition to malignant 
diseases aﬀ ecting other parts of the body.3 Tumours that 
are commonly associated with the disorder include glioma 
of the optic pathway, glioblastoma, malig nant peripheral 
nerve sheath tumour, gastrointestinal stromal tumour, 
breast cancer, leukaemia, phaeo chromo cytoma, duodenal 
carcinoid tumour, and rhabdo myo sarcoma (table).4–13
Neuroﬁ bromatosis type 1 was ﬁ rst described by Frederich 
von Recklinghausen in 1882. In 1987, formal diagnostic 
criteria were published by the National Institutes of Health 
(panel).14 In this Review, we describe benign and malig-
nant features of neuroﬁ bromatosis type 1, focusing on 
diagnostic strategies, monitoring, and treatment of 
tumours located in the nervous system and elsewhere. 
Additionally, we highlight possible future therapeutic 
directions based on ﬁ ndings of preclinical drug discovery 
and evaluation studies in genetically engineered mouse 
models of neuroﬁ bromatosis type 1-associated malignant 
diseases. Finally, we discuss current and future clinical 
trials in patients with neuro ﬁ bromatosis type 1.
Genetics and genetic testing
Neuroﬁ bromatosis type 1 is a dominantly inherited 
genetic disorder that results from a germline mutation in 
the NF1 tumour-suppressor gene. NF1 is located on 
chromosome 17q11.2 and encodes a 220 kDa cytoplasmic 
protein called neuroﬁ bromin. This protein functions, in 
part, as a negative regulator of the Ras proto-oncogene, 
which is a key signalling molecule in the control of cell 
growth.15 Aﬀ ected individuals start life with one mutated 
(non-functional) copy and one functional copy of NF1 in 
every cell in their body. Although many of the clinical 
features of this syndrome are apparent from birth, 
complete loss of gene function is needed for formation of 
tumours, by acquisition of a somatic NF1 mutation in 
selected cells.16,17
About 50% of individuals with neuroﬁ bromatosis type 1 
have no family history of the disease and the disease is due 
to de novo (spontaneous) mutations. With the advent of 
accurate genetic testing, early genotype-phenotype 
correlations are beginning to emerge, including the 
observation that people with genomic microdeletions 
aﬀ ecting the entire NF1 gene have a more severe 
phenotype.18,19 For instance, this particular subgroup of 
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Lifetime risk
Glioma of the optic pathway 15–20%
Other brain tumour More than ﬁ vefold increase
Malignant peripheral nerve-sheath tumour 8–13%
Gastrointestinal stromal tumour 4–25%
Breast cancer About ﬁ vefold increase
Leukaemia About sevenfold increase
Phaeochromocytoma 0·1–5·7%
Duodenal carcinoid tumour 1%
Rhabdomyosarcoma 1·4–6%
Table: Lifetime risk of diﬀ erent tumours in children and adults with 
neuroﬁ bromatosis type 1
Panel: NIH consensus criteria14 for diagnosis of 
neuroﬁ bromatosis type 1
Two or more of the following clinical features are suﬃ  cient to 
establish a diagnosis of neuroﬁ bromatosis type 1:
• Six or more café-au-lait macules (>0·5 cm at largest 
diameter in a prepubertal child or >1·5 cm in post-pubertal 
individuals)
• Axillary freckling or freckling in inguinal regions
• Two or more neuroﬁ bromas of any type or one or more 
plexiform neuroﬁ bromas
• Two or more Lisch nodules (iris hamartomas)
• A distinctive osseous lesion (sphenoid wing dysplasia, 
long-bone dysplasia)
• An optic pathway glioma
• A ﬁ rst-degree relative with neuroﬁ bromatosis type 1 
diagnosed by the above criteria
NIH=National Institutes of Health.
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individuals with NF1 microdeletions tend to develop 
neuroﬁ bromas at an earlier age, have a lower mean IQ, 
manifest abnormal facial features, and are at increased 
risk of developing malignant peripheral nerve-sheath 
tumours.19–21 At present, the diagnosis of neuroﬁ bromatosis 
type 1 is most commonly made using established clinical 
criteria,14 reserving NF1 genetic testing for unusual 
presentations or reproductive decision-making.
Non-malignant clinical features
Pigmentary abnormalities  
Frequently, the earliest clinical manifestation of neuro-
ﬁ bromatosis type 1 is café-au-lait macules, which usually 
develop within the ﬁ rst 2 years of life (ﬁ gure 1). 
The presence of more than ﬁ ve café-au-lait macules 
(>0·5 cm in diameter before puberty or >1·5 cm after 
puberty) is one of the diagnostic criteria for neuro-
ﬁ bromatosis type 1. These lesions have no malignant 
potential and tend to darken with sun exposure and fade 
with advancing age. For macules that reduce quality of life, 
individuals can be oﬀ ered dermatological camouﬂ age 
treatments.22
Axillary and inguinal freckling is another common 
clinical feature of neuroﬁ bromatosis type 1 and is 
usually detected in aﬀ ected individuals by age 5–8 years. 
These pigmentary abnormalities are typically the second 
diagnostic characteristic seen in children with the 
disorder, generally arising after development of café-
au-lait macules. Freckles can also be found in areas 
where skinfolds are in apposition, including the neck 
and under the breasts in women.23
Lisch nodules are benign melanocytic hamartomas of 
the iris, typically ﬁ rst noticed in children aged 5–10 years. 
Nearly all adults with neuroﬁ bromatosis type 1 have 
Lisch nodules. These pigmented lesions are best detected 
on slit-lamp examination by an experienced ophthal-
mologist.23 Lisch nodules do not impair vision or cause 
any medical problems.
Neuroﬁ bromas  
Neuroﬁ bromas are benign Schwann-cell tumours 
composed not only of neoplastic Schwann cells24,25 but 
also of non-neoplastic ﬁ broblasts, mast cells, macro-
phages, endothelial cells, pericytes, and perineural 
cells.26–29 There are four subtypes: cutaneous, sub-
cutaneous, nodular or diﬀ use plexiform, and spinal.
Intracutaneous neuroﬁ bromas develop during late 
childhood or early adolescence and do not undergo 
malignant transformation. Owing to an abundance of 
mast cells associated with the tumours, these tumours 
might cause local pruritus. Intracutaneous neuro ﬁ bromas 
can result in substantial discomfort or disﬁ gure ment 
when hundreds or thousands of these neuroﬁ bromas are 
present in a patient. In such instances, the tumours can 
be removed by a plastic surgeon.22 Spinal neuroﬁ bromas 
can occur at single or multiple nerve roots and are 
associated with both sensory and motor deﬁ cits.
Although neuroﬁ bromas are commonly found on the 
skin—presenting as subcutaneous, dermal, or exophytic 
masses—they can also be located deep within the body. 
Individuals with neuroﬁ bromatosis type 1 generally 
develop more neuroﬁ bromas as they get older, and some 
patients can have many deep neuroﬁ bromas without 
clinical symptoms. In these patients, tumour removal 
should be led by symptoms—such as pain and functional 
deﬁ cits—and ﬁ ndings of a risk-beneﬁ t assessment.
Plexiform neuroﬁ bromas  
Plexiform neuroﬁ bromas typically manifest at birth but can 
continue to grow during adolescence and early adulthood 
(ﬁ gure 2). In most individuals, these tumours enlarge most 
prominently during the ﬁ rst decade of life. Plexiform 
neuroﬁ bromas develop in about 30–50% of individuals 
Figure 1: Café-au-lait macule
Macule on a 24-year-old woman with neuroﬁ bromatosis type 1 who was 
diagnosed as a young child (measuring tape shown for reference). 
Figure 2: Internal plexiform neuroﬁ broma
Coronal MRI shows an extensive neuroﬁ broma (asterisk) in an 8-year-old boy 
with neuroﬁ bromatosis type 1. 
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with neuroﬁ bromatosis type 1. They diﬀ er from cutaneous 
neuroﬁ bromas in that they arise from multiple nerve 
fascicles and can grow along the length of a nerve.30 These 
tumours can also extend into surroun ding structures, 
causing substantial pain and bone destruction. Importantly, 
plexiform neuroﬁ bromas have a lifetime risk of malignant 
transformation. Although the best therapeutic option for 
symptomatic lesions is surgical removal, this approach is 
sometimes technically impossible.3
Chemotherapy is a potential therapeutic option for 
plexiform neuroﬁ bromas. In a recent phase 1 trial, 
pegylated interferon-alfa-2b (antiviral cytokine therapy)
was assessed in 30 patients with plexiform neuroﬁ bromas 
who had radiographic progression before enrolment.31 
Reported eﬀ ects were pain reduction (in 11 of 16 patients), 
decreased tumour mass (13 of 14), and tumour shrinkage 
or stabilisation (three of four). Similarly, in a phase 2 trial 
of imatinib (tyrosine kinase inhibitor), 17% of patients 
with plexiform neuroﬁ bromas had a 20% or more 
reduction in tumour volume.32 In view of these initial 
encouraging results, several studies are now in progress 
to test the use of other biologically targeted therapies, 
including mammalian target of rapamycin (mTOR) 
inhibitors and mitogen-activated protein kinase kinase 
(MEK) inhibitors in these patients.
Skeletal deformities  
People with neuroﬁ bromatosis type 1 can develop skeletal 
abnormalities, including osteopenia, scoliosis, sphenoid 
wing dysplasia, congenital tibial dysplasia, and 
pseudarthrosis (ﬁ gure 3). Moreover, aﬀ ected individuals 
tend to be shorter than expected for their age and 
frequently have low bone-mineral densities.33 In a large 
registry-based study of neuroﬁ bromatosis type 1, a 
roughly ﬁ vefold increase in fracture risk was reported for 
adults older than 40 years, and this risk was about 
threefold higher in children younger than 16 years.34 
Lifestyle modiﬁ cations such as increased exercise and 
calcium or vitamin D supplementation might be 
warranted in these patients. Low concentrations of 
vitamin D have been recorded in people with 
neuroﬁ bromatosis type 1.33,35–38 In a retro spective study of 
vitamin D supplementation, loss of bone-mineral density 
was reduced signiﬁ cantly in adult patients with 
neuroﬁ bromatosis type 1 whose vitamin D levels were 
maintained above 30 μg/L, compared with people who 
had not been supplemented.39 Although this ﬁ nding 
suggests that all adults should be screened for vitamin D 
deﬁ ciency and appropriate replacements initiated, 
prospective studies are needed before practice recom-
mendations are changed.
Scoliosis can aﬀ ect 10–26% of individuals with 
neuroﬁ bromatosis type 1, making annual spinal 
examinations necessary during childhood and early 
adolescence.40 Mild curvature can be treated with bracing; 
however, more severe cases might need surgery to 
stabilise progressive spinal and chest-wall deformity 
and preserve lung function by minimising constrictive 
forces.3 The vertical expandable prosthetic titanium rib 
(VEPTR), which is used to diminish constrictive forces 
on the lung, has shown promise in clinical trials.41 It is 
noteworthy that some individuals with neuroﬁ bromatosis 
type 1 have dystrophic scoliosis with striking curvatures 
and generally less satisfactory surgical outcomes than 
those without striking curvatures.
Sphenoid wing dysplasia typically presents as a unilateral 
bony defect aﬀ ecting the orbital plate and the frontal bone. 
Sometimes, thinning or absence of the sphenoid wing is 
attributable to the presence of an associated orbital 
plexiform neuroﬁ broma, but it can occur as an isolated 
bony abnormality.42 These defects are usually seen in 
Figure 3: Skeletal abnormalities in individuals with neuroﬁ bromatosis type 1
Plain ﬁ lm radiographs showing: (A) dystrophic scoliosis (asterisk) in an 11-year-old girl; (B) tibial bowing (asterisk) 
in a 10-month-old baby girl; (C) tibial pseudarthrosis (asterisk) in a 9-month-old baby girl; and (D) tibial 
pseudarthrosis after insertion of an internal rod (asterisk) in a 9-year-old boy. 
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asymptomatic individuals after a careful physical 
examination in which one eye appears asymmetric or is 
proptotic or sunken. Congenital tibial dysplasia generally 
presents as anterolateral bowing of the lower leg, with 
cortical thinning evident on plain radiographs. The 
presence of bowing in an infant should warrant prompt 
radiographic assessment. Repeated fractures with failure 
to heal can lead to development of pseudarthrosis and, in 
some cases, limb amputation.43 Referral to a skilled 
paediatric orthopaedic surgeon is needed to initiate 
appropriate treatment and avoid this poor outcome.
Cardiovascular abnormalities  
Individuals with neuroﬁ bromatosis type 1 can develop 
various cardiovascular abnormalities, ranging from con-
genital heart disease to vasculopathy and hyper tension. 
Echocardiographic data suggest that up to 27% of patients 
with neuroﬁ bromatosis type 1 have a cardio vascular 
anomaly,44 and pulmonary artery stenosis accounts for as 
many as 50% of these abnormalities.45 The prevalence of 
abnormalities is likely to be an under estimate because a 
diagnosis is usually made only if symptoms develop. 
Therefore, all children born with neuroﬁ bromatosis 
type 1 should have a thorough cardiac examination and 
any murmurs should be investigated further by a skilled 
paediatric cardiologist.46
Neuroﬁ bromatosis type 1-related vasculopathy includes 
renal and cerebral artery stenosis, aortic coarctation, 
and arteriovenous malformations.47 The pathogenesis, 
clinical spectrum, and natural history of these anomalies 
remains poorly understood; however, impaired NF1 gene 
function in vascular endothelial cells results in increased 
proliferation and growth.27,48,49 Vasculopathy usually 
aﬀ ects the arterial system, leading to cerebrovascular 
disease (eg, narrowed or ectatic vessels, vascular stenosis, 
aneurysm, or moyamoya disease) or renal artery 
stenosis.47,50,51 Individuals with neuroﬁ bromatosis type 1 
who present with a new neurological deﬁ cit should be 
assessed for both cerebrovascular disease and brain 
tumour. Moreover, any patient with unexplained hyper-
tension should undergo investigation for renal artery 
stenosis. Laboratory assessments (serum creatinine and 
electrolytes, plasma renin, and urinalysis), approp riate 
imaging studies, and arteriography are important. 
Although essential hypertension remains the most 
common reason for raised blood pressure in this 
population, other causes include coarctation of the aorta 
and phaeochromocytoma. Some of these abnormalities 
are likely to be congenital; however, whether vascular 
stenoses are actually present at birth is unclear. Further 
study is needed to resolve these uncertainties.
Neurocognitive deﬁ cits  
Neurocognitive deﬁ cits are among the most common 
manifestations of neuroﬁ bromatosis type 1. Children 
should undergo neuropsychological screening assess-
ments early in life, followed by more detailed testing 
when appropriate.52 Learning diﬃ  culties can include 
visuospatial and visuomotor deﬁ cits, language 
disorders, and ﬁ ne and gross motor deﬁ ciencies. 
Furthermore, attention-deﬁ cit hyperactivity disorder, 
autism spectrum disorders, behavioural abnormalities, 
and psychosocial issues are prevalent in this 
population.53 Children with neuro ﬁ bro matosis type 1 
might beneﬁ t from a multi disciplinary approach, in 
which educational specialists, paediatric neuro -
psychologists, physical thera pists, speech therapists, 
and occupational therapists work together to maximise 
abilities and optimise the chance for academic and 
social success. Pharmacological inter ven tions with 
treatments such as lovastatin54 or drugs used to treat 
attention-deﬁ cit hyperactivity disorder (eg, methyl-
phenidate) might be of beneﬁ t for some children.
Nervous-system tumours
Optic pathway and brainstem gliomas  
About 15–20% of individuals with neuroﬁ bromatosis 
type 1 will develop low-grade glial neoplasms; roughly 
80% are in the optic pathway, but some (15%) can be 
present in the brainstem,22 with rare involvement of the 
cerebellum, cortex, and subcortical regions.5 Optic 
pathway gliomas (ﬁ gure 4A) typically present in children 
with neuro ﬁ bromatosis type 1 who are younger than 
7 years.55 These tumours are mainly WHO grade I glial 
neoplasms—termed pilocytic astrocytomas—and are 
indistinguishable histologically from gliomas that arise 
sporadically in individuals without neuroﬁ bromatosis 
type 1.56 Although many optic pathway gliomas are 
asymptomatic, up to half can cause clinical symptoms, 
most commonly resulting in reduced vision; some 
children present with precocious puberty.57
Owing to the frequency of optic pathway gliomas in 
young children with neuroﬁ bromatosis type 1, all patients 
who are younger than 13 years should undergo an 
Figure 4: Low-grade glial neoplasms
(A) MRI showing an optic glioma in the left optic nerve (asterisk) of a 4-year-old boy with neuroﬁ bromatosis 
type 1. (B) MRI showing a brainstem glioma (asterisk) in a 9-year-old boy with neuroﬁ bromatosis type 1.
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ophthal mological examination every year by a paediatric 
neuro-ophthalmologist. Screening MRI is not recom-
mended unless children are unable to undertake the 
ophthalmological assessment and reliable measure ments 
of visual acuity cannot be obtained.55 On identiﬁ cation of 
an optic glioma, current recommendations include 
ophthalmological and MRI studies four times a year for 
the ﬁ rst year, followed by gradual lengthening of test 
intervals over the next 2–3 years. A two-line decrease in 
visual acuity, as measured by a standardised visual 
assessment procedure such as the Snellen chart, warrants 
referral to a paediatric neuro-oncologist for treatment.58
Surgery plays little part in the treatment of optic 
pathway gliomas because it can result in permanent 
neurological damage.58 First-line treatment for most 
patients with symptomatic tumours is chemotherapy 
with carboplatin and vincristine.59 Other chemotherapy 
combinations have been used; however, no randomised 
trial data are available to support the use of one regimen 
over another.60 Cranial radiation therapy is not recom-
mended for patients with neuroﬁ bromatosis type 1 
because of the increased propensity of this population to 
develop second malignancies, vascular abnormalities, 
and neuropsychological diﬃ  culties.10,61
Brainstem gliomas are the most frequently discovered 
brain tumor outside of the optic pathway in people with 
neuroﬁ bromatosis type 1.22 Similar to optic pathway 
tumours, brainstem gliomas (ﬁ gure 4B) are usually 
pilocytic astrocytomas; however, they typically present 
later in the ﬁ rst decade of life. Aﬀ ected children might 
come to medical attention with cranial neuropathies, 
lethargy, gait instability, or headaches. Chemotherapy is 
used to treat clinically progressive tumours, with drugs 
such as carboplatin or vincristine, as would be 
administered for other low-grade gliomas in the 
paediatric population.
Glioblastomas  
Individuals with neuroﬁ bromatosis type 1 have at least a 
ﬁ vefold increased risk for developing other brain 
tumours, including WHO grade IV astrocytomas (glio-
blastomas), according to ﬁ ndings of several case reports 
and small retrospective studies.9,62–64 Glioblastomas 
usually present in young adults,65 in whom the overall 
prognosis is poor. Treatment is similar to that for people 
with sporadic glioblastomas and usually entails gross 
surgical resection followed by adjuvant radiation and 
chemotherapy (typically oral temozolomide).
Malignant peripheral nerve sheath tumours  
Malignant peripheral nerve sheath tumours—
sometimes referred to as neuroﬁ brosarcomas or 
neurogenic sarcomas—are a subtype of sarcoma with a 
presumed Schwann cell origin. These tumours represent 
about 3–10% of all soft-tissue sarcomas, and a large 
proportion arise in individuals with neuro ﬁ bromatosis 
type 1.66 Malignant peripheral nerve sheath tumours 
have a prevalence of 0·001% in the general population 
versus 0·1% in individuals with neuro ﬁ bromatosis 
type 1.6,67 The cumulative lifetime risk of developing 
malignant peripheral nerve sheath tumours in a patient 
with neuroﬁ bromatosis type 1 is about 8–13%.68 Malig-
nant peripheral nerve sheath tumours can arise any-
where within the body. Risk for developing a malignant 
peripheral nerve sheath tumour is increased 20-fold in 
the area of an existing internal plexiform neuroﬁ broma.69 
Other risk factors for development of malignant peri-
pheral nerve sheath tumours include previous radia tion 
therapy and large germline mutations encompassing the 
entire NF1 gene (microdeletions).21
Individuals with neuroﬁ bromatosis type 1 who report 
substantial or diﬃ  cult-to-control pain, a rapid increase in 
the size of an existing plexiform neuroﬁ broma, a change 
in tumour consistency (soft to hard), or a new neurological 
deﬁ cit warrant prompt assessment for malignant 
peripheral nerve sheath tumours.67 MRI is helpful to 
deﬁ ne the location and extent of the tumour, but it is not 
reliable for distinguishing between malignant disease 
and benign tumours. Over the past decade, ¹⁸F-ﬂ uoro-
deoxy glucose (¹⁸F-FDG)-PET has emerged as a highly 
sensitive and speciﬁ c method for detection of malignant 
peripheral nerve sheath tumours (ﬁ gure 5).70–72 Needle 
biopsy can be aﬀ ected by sampling bias and might not 
allow the treating clinician to exclude a diagnosis of 
malignant peripheral nerve sheath tumour with 
conﬁ dence.67 Furthermore, patients with suspected 
malignant disease should be examined for evidence of 
metastatic disease (eg, in the lung or bone). In view of 
the aggressive nature of malignant peripheral nerve 
sheath tumours, patients should be assessed and 
managed by a multidisciplinary team including 
neurologists, radiologists, surgeons, oncologists, and 
radiation oncolo gists to eﬃ  ciently implement plans for 
biopsy (non-invasive or open) and treatment.
Surgery is the only curative treatment option for patients 
with malignant peripheral nerve sheath tumours.73 Even 
with surgical excision, 5-year overall survival rates are 
poor,6,74 and this cancer represents a substantial cause of 
mortality in individuals with neuroﬁ bromatosis type 1.9 
Some ﬁ ndings suggest that survival is beginning to 
increase, particularly in women; however, this rise might 
be attributable to heightened recognition and identiﬁ cation 
of malignant peripheral nerve sheath tumours at an earlier 
stage.75 Although radiation therapy could delay time to 
recurrence, this treatment does not change time to death.67,76 
Use of adjuvant chemotherapy is controversial.77,78 In some 
instances, chemotherapy can be used in the neoadjuvant 
setting to downstage tumours before resection; however, 
this practice has not been adopted widely.67 Clinical studies 
of promising chemotherapy drugs are underway in 
individuals with neuroﬁ bromatosis type 1-associated 
malignant peripheral nerve sheath tumours. In patients 
with metastatic disease, single-agent anthracycline is the 
most accepted form of palliative care.67,79
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Non-nervous-system tumours
Gastrointestinal stromal tumours  
Gastrointestinal stromal tumours are of mesenchymal 
origin and can develop anywhere along the gastro-
intestinal tract. Compared with the general population, 
individuals with neuroﬁ bromatosis type 1 are slightly 
younger at presentation (median age 50 years vs 
60 years)80,81 and about 95% are asymptomatic. Moreover, 
patients with neuroﬁ bromatosis type 1 and gastro-
intestinal stromal tumours more frequently present with 
multiple tumours compared with the general popu lation.82 
The most common symptoms reported are abdominal 
pain, bleeding, intestinal perforation, and intestinal 
obstruction.66,83 Gastrointestinal stro mal tumours can be 
an incidental ﬁ nding during imaging studies, might be 
spotted during surgery to remove another tumour, or 
could be diagnosed from presenting symptoms.
In the general population, gastrointestinal stromal 
tumours are associated with increased expression of the 
KIT and PDGFRA transmembrane receptors. Activation 
of these receptor tyrosine kinases drives proliferation, 
providing the scientiﬁ c basis for treatment with 
imatinib.80,84 By contrast, in patients with neuro ﬁ bro-
matosis type 1, gastrointestinal stromal tumours typically 
do not overexpress KIT or PDGFRA,85 which limits the 
use of imatinib in this population.86,87 Currently, the only 
treatment option for neuro ﬁ bromatosis type 1-associated 
gastro intestinal stromal tumours is surgery, if feasible. 
Clinical trials of other tyrosine kinase receptor inhibitors 
(eg, sunitinib) are ongoing in patients with metastatic 
disease.88
Breast cancers  
A ﬁ vefold increased risk for breast cancer has been 
reported in individuals with neuroﬁ bromatosis type 1, 
mainly aﬀ ecting women younger than 50 years.8,13,89,90 
Furthermore, mortality rates in women with neuro-
ﬁ bromatosis type 1 and breast cancer are higher than 
those for women with breast cancer in the general 
population.91 Although reported studies include only 
a few patients, relative risks are similar to those for 
people with a family history of breast cancer. Women 
age 30–49 years with neuroﬁ bromatosis type 1 could 
undergo early mammography or MRI;92 however, large 
prospective studies are needed before formal recom-
mendations can be made about screening in this 
population. Currently, treatment for neuroﬁ bromatosis 
type 1-associated breast cancer does not diﬀ er from that 
for women with breast cancer in the general population.
Leukaemia and lymphoma  
Children with neuroﬁ bromatosis type 1 have at least a 
sevenfold higher risk for developing myeloid leukaemia 
compared with children in the general population,93 and 
the prevalence of chronic myelomonocytic leukaemia, 
juvenile chronic myelogenous leukaemia, acute lympho-
cytic leukaemia, and non-Hodgkin lymphoma is also 
raised.94,95 However, these tumours are rare in people 
with neuroﬁ bromatosis type 1. Moreover, no evidence is 
available to support a diﬀ erence in prognosis between 
neuroﬁ bromatosis type 1-associated leukaemia and 
lymphoma relative to the general population. Treatments 
for neuroﬁ bromatosis type 1-associated leukaemia 
parallel those used for individuals without neuro-
ﬁ bromatosis type 1.95
Phaeochromocytoma  
Phaeochromocytomas—catecholamine-secreting tumours 
of the adrenal medulla or other sites in the sympathetic 
nervous system—are seen at increased frequency in 
individuals with neuroﬁ bromatosis type 1. These tumours 
arise in 0·1–5·7% of people with neuroﬁ bromatosis 
type 1 compared with 0·002–0·008% of the general 
population. The age of onset (typically the fourth decade 
of life) is similar in neuroﬁ bromatosis type 1-associated and 
sporadic cases.12,96 Phaeochromocytomas should be sus-
pected in an individual with neuroﬁ bromatosis type 1 who 
presents with unexplained hypertension, ﬂ ushing, 
Figure 5: Malignant peripheral nerve-sheath tumours
¹⁸F-FDG-PET images showing malignant peripheral nerve-sheath tumours (asterisks) in (A) a 24-year-old woman 
and (B) a 29-year-old man, both with neuroﬁ bromatosis type 1. FDG=ﬂ uorodeoxyglucose.
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headaches, sweating, or heart palpitations. Diagnosis is 
established typically with a combination of imaging 
studies (CT or MRI of the chest and abdomen or a 
meta-iodobenzyl -guanidine scan or somatostatin scinti-
graphy if CT is negative) and biochemical assessments 
(eg, the amount of catecholamines in urine).97 Surgery is 
curative for resectable disease,98 whereas chemotherapy or 
radio pharmaceutical treatment with ¹³¹I-meta-iodobenzyl-
guanidine is used for metastatic or unresectable cancers.99,100
Duodenal carcinoids  
Carcinoid tumours are neuroendocrine tumours that arise 
from endocrine cells within the gastrointestinal tract; they 
are reported in about 1% of individuals with neuro-
ﬁ bromatosis type 1.7,101 The most common site for carcinoid 
tumours is the periampullary region;4,66 therefore, indivi-
duals usually present with jaundice and non-speciﬁ c 
abdominal pain. In patients with neuroﬁ bromatosis type 1, 
these tumours generally present at a young age.101,102 
The diagnosis of carcinoid tumours is typically made with 
a combination of imaging studies—eg, CT of the chest, 
abdomen, and pelvis, somatostatin scintigraphy, and 
endoscopic ultrasound or endoscopy—and measure ment 
of urinary and serum 5-hydroxyindolectic acid and chroma-
granin A, when clinically appropriate.101 Surgical resection 
should be done if possible; unresectable and metastatic 
disease is treated generally with somatostatin analogues or 
chemotherapy.101,103
Rhabdomyosarcomas  
Rhabdomyosarcomas are non-neurogenic sarcomas 
composed of small round blue cells that probably 
originate from the neural crest.66 Children with neuro-
ﬁ bromatosis type 1 have about a 20-fold increased risk of 
developing these tumours.11 Rhabdomyosarcomas most 
commonly present as palpable masses. Manage ment 
relies on surgical resection when feasible, whereas 
adjuvant chemotherapy and radiation therapy might be 
appropriate for some individuals.104,105
Conclusions and future directions
Over the past 15 years, substantial advances have been 
made in our ability to discover, validate, and translate 
laboratory-based research ﬁ ndings to the clinical work-
place. Many accurate preclinical models of neuro-
ﬁ bromatosis type 1-associated malignant disease in 
genetically engineered mice have been developed and used 
as platforms to evaluate rational targeted treatments. 106–114 
Although these models have some limitations, they have 
already proven useful in the design and implementation of 
human clinical trials. 
After identiﬁ cation of NF1 as a negative Ras regulator,115–117 
ﬁ ndings of several preclinical studies in Nf1-deﬁ cient mice 
have shown that inhibition of down stream targets of 
Ras attenuates Nf1-deﬁ cient tumour cell growth in vitro 
and in vivo. For example, in studies of genetically 
engineered Nf1 mice, rapamycin analogues (eg, everolimus) 
and MEK inhibitors were eﬀ ec tive biologi cally targeted 
treatments for neuroﬁ bro ma tosis type 1-associated 
plexiform neuro ﬁ broma,118,119 and rapamycin analogues 
and chemokine recep tor inhibitors were assessed for 
neuroﬁ bromatosis type 1-associated glioma and malignant 
peripheral nerve sheath tumours.120–123
Models of optic pathway glioma109,124 and plexiform 
neuroﬁ broma108 in genetically engineered Nf1 mice 
showed that non-cancerous stromal cells (tumour 
microenvironment) have important roles in tumour 
development and growth. Loss of Nf1 in Schwann cell 
and astroglial cell precursors alone was not suﬃ  cient for 
tumorigenesis; loss of Nf1 expression in Schwann cell or 
astroglial cell precursors must occur in Nf1+/− mice 
(genetically comparable with individuals with neuro-
ﬁ bromatosis type 1) for neuroﬁ bromas and optic 
gliomas, respectively, to form.108,109,124 Further investigation 
of participatory stromal cell types in models of optic 
pathway gliomas and plexiform neuroﬁ bromas in 
genetically engineered Nf1  mice indicates an obligatory 
role for microglia and mast cells, respectively, in the 
genesis and maintenance of these tumours.125–127 
The ﬁ nding that mast cells are important micro-
environmental drivers of plexiform neuroﬁ broma 
growth culminated in use of imatinib to inhibit c-kit 
function in preclinical studies in Nf1 mice and the 
translation of these results to human clinical trials.32
Although studies of these genetically engineered Nf1 
mice hold substantial promise, future studies need to 
report clearly positive ﬁ ndings to facilitate eﬀ ective 
translation to human clinical trials. Thus, preclinical 
response criteria should incorporate the proportion of 
mice with signiﬁ cant radiographic responses, the 
durability of these outcomes, and the extent of tumour 
shrinkage. Pharmacokinetic and pharmacodynamic 
considerations will also need to be integrated into these 
criteria to ensure a high likelihood of success in patients.
With the establishment of the Neuroﬁ bromatosis 
Clinical Trials Consortium (NFCTC),128 therapeutic trials 
in large numbers of individuals with neuroﬁ bromatosis 
type 1-associated malignant disease can now be under-
taken eﬃ  ciently. Up to now, the NFCTC has initiated 
several clinical trials, including studies of sorafenib for 
neuroﬁ bromatosis type 1-associated plexiform neuro-
ﬁ bromas (NCT00727233), bevacizumab and everolimus 
for malignant peripheral nerve sheath tumours 
(NCT01661283), everolimus for progressive neuro-
ﬁ bromatosis type 1-associated glioma (NCT01158651), 
Search strategy and selection criteria
We searched PubMed between January, 1970, and March, 2014, with the terms: 
“NF1”, “skin”, “bone”, “cardiovascular”, “neurocognitive”, “plexiform”, “malignancy”, 
“optic pathway glioma”, “GBM”, “MPNST”, “breast cancer”, “leukemia”, “GIST”, 
“pheochromocytoma”, “duodenal carcinoids”, and “rhabdomyosarcoma”. We also chose 
references from selected articles. We did not restrict our search by language.
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MEK inhibitors for children with inoperable neuro-
ﬁ bromatosis type 1-associated plexiform neuro ﬁ bromas 
(NCT01362803), and MEK inhibitors for patients with 
tumours activated by RAS, RAF, or MEK, including 
those with mutations in the NF1 gene (NCT01885195).
Tumours that develop in patients with neuro ﬁ bromatosis 
type 1 are heterogeneous from a molecular and cellular 
perspective and, therefore, represent complex cancers in 
which distinct cell types and growth-control pathways 
regulate tumour behaviour. With availability of accurate 
preclinical mouse models for most tumour types in 
neuroﬁ bromatosis type 1, a detailed understanding of 
neuroﬁ bromin-controlled signalling pathways, and avail-
ability of a clinical trials infrastructure for rapid drug 
evaluation, we can now envision a future in which 
eﬀ ective treatments for people with neuroﬁ bromatosis 
type 1-associated tumours are imminent.
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